In comparison to amyloid PET and CSF testing, BBMs have major practical advantages that may enable broader use for AD biomarker testing. These include acceptability of blood draws by patients, accessibility of equipment and staff, and lower costs3. However, clinically available BBMs have widely vari...
Blood plasma %p-tau217 demonstrated performance that was clinically equivalent or superior to clinically used FDA-approved CSF tests in the detection of AD pathology. Use of high-performance blood tests in clinical practice can improve access to accurate AD diagnosis and AD-specific treatments....
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and ne
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and ne
However, the widespread implementation of these biomarkers to facilitate patient screening in clinical trials or in routine clinical practice is hampered by their invasiveness, costs and limited availability. Thus, more accessible and cost-effective diagnostic approaches, such as blood-based biomarkers, ...
Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2021;21:66–77. Article PubMed Google Scholar Alawode DOT, Heslegrave AJ, Ashton NJ, Karikari TK, Simrén J, Montoliu-Gaya L, et al. Transitioning from cerebrospinal fluid to blood tests to ...
Whole blood samples from 508 participants in the J-ADNI cohort and post-mortem frontal cortices from 577 donors in the NP cohort were genotyped using the Infinium Asian Screening Array (Illumina), containing 657,490 SNPs. APOE genotypes in each participant were determined by haplotypes derived fr...
However, the administration of these drugs presents challenges owing to the invasiveness, high cost and limited availability of amyloid-PET and cerebrospinal fluid tests for guiding drug administration. Our manuscript explores the potential of less invasive blood biomarkers as a diagnostic method, with ...
Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance. The Global CEO Initiative on Alzheimer’s Disease convened a BBM Workgroup to consider the minimum ...
suitable for large-scale screening due to their invasiveness, high cost and low accessibility. Considering the greater availability of blood sampling, blood-based biomarkers become the primary goal in screening for and diagnosing AD in the population and many studies now focus on examining the role ...